Summary: Findings revealed a profound therapeutic benefit: GLP-1 receptor agonists (such as semaglutide, tirzepatide, and liraglutide) do not merely drive physical weight reduction. Instead, they actively downregulate the core behavioral features of BED, significantly reducing active binge eating episodes, loss-of-control eating, and emotional eating patterns.
